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Abstract
Background This study was performed to evaluate the
treatment of complex regional pain syndrome (CRPS) type
I with stellate ganglion blockade.
Materials and methods We performed three blockades at
weekly intervals in 22 patients with CRPS type I in one
hand. The patients were divided into two groups depending
on the time between symptom onset and treatment initia-
tion. Group 1and 2 patients had short and long symptom-
onset-to-treatment intervals, respectively. Pain intensity,
using a visual analog score (VAS), and range of motion
(ROM) for the wrist joint were assessed before and
2 weeks after treatment and were compared using non-
parametric statistical analysis.
Results Treatment produced a statistically signiﬁcant
difference in wrist ROM for all patients (P\0.001). VAS
values showed an overall decrease from 8 ± 1t o1± 1
following treatment, and there was a signiﬁcant difference
in VAS value between groups 1 and 2 (P\0.05).
Conclusions We concluded that stellate ganglion block-
ade successfully decreased VAS and increased ROM of
wrist joints in patients with CRPS type I. Further, the
duration between symptom onset and therapy initiation was
a major factor affecting blockade success.
Keywords Complex regional pain syndrome type I 
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Introduction
Complex regional pain syndrome (CRPS) was once known
as reﬂex sympathetic dystrophy (RSD) and causalgia [1].
The International Association for the Study of Pain (IASP)
suggested a new nomenclature, CRPS, with two subtypes,
which deliberately avoid suggesting etiology or site [2].
CRPS type I (RSD) is deﬁned as a syndrome that usually
starts after a noxious event, is not limited to the distribution
of a single peripheral nerve, and is disproportionate to the
inciting event [3]. CRPS type II (causalgia) is deﬁned as a
syndrome that starts after a nerve injury and is not neces-
sarily limited to the distribution of the injured nerve [3].
Despite these changes, CRPS has generated signiﬁcant
research interest [4]. One issue that continues to evolve is
the role of interventional therapy in managing CRPS type I
[5]. The sympathetic nervous system has been implicated
in the pathophysiology of CRPS type I, and consequently,
sympathetic nervous system blockade is widely used to
treat CRPS type I [6]. The current view is that, when
necessary, interventions administered in a timely manner
may help relieve pain and facilitate the primary goal—
functional rehabilitation of the affected limb [7].
Although treatment of CRPS type I with stellate gan-
glion block is well established, there is a limited number of
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review published by Cepeda et al. [6] revealed the scarcity
of published evidence to support the use of local anesthetic
sympathetic blockade as the gold standard treatment for
CRPS.
The purpose of this prospective study was to evaluate
the effectiveness of stellate ganglion blockade in CRPS
type I in improving functional use of the affected limb and
thus increase the patient’s independence at work, at leisure,
and in the performance of daily activities.
Materials and methods
The study consisted of 22 patients admitted to the Ortho-
paedics and Traumatology Department of our hospital
between 2003 and 2006 with the diagnosis of CRPS type I
in one hand (Table 1). The diagnosis was based on the
IASP diagnostic criteria [2, 8]. The inclusion criteria were
the presence of regional pain and sensory changes fol-
lowing a noxious event; pain associated with ﬁndings such
as abnormal skin color, temperature change, abnormal
sudomotor activity or edema; no distribution of the pain of
a single nerve in the extremity; the combination of these
ﬁndings exceeding their expected magnitude in response to
known physical damage during and following the inciting
event [8]. Prior treatment with conservative therapies, such
as medication, physical therapy, and rehabilitation pro-
grams, was not successful in these patients. Exclusion
criteria were use of tobacco products or any medication
that could affect sympathetic function, active infection at
the injection site, known allergies to medications, previous
neck surgeries, Raynaud’s disease or Raynaud’s phenom-
ena, and coagulopathy. The study was approved by our
Institutional Review Board, and the study protocol con-
formed to the ethical guidelines of the 1975 Declaration of
Helsinki as reﬂected in a prior approval by our Institutional
Review Board. Written informed consent was obtained
from each patient.
Twenty-two patients with diagnosis of CRPS type I [12
right (54.5%) and ten left (45.5%)] were included. Thirteen
patients were women (59.1%) and nine (41.9%) were men.
Mean patient age was 50.7 ± 15.0 (range 18–70) years,
59.3 ± 22.3 (range 27–85) years, and 54.6 ± 18.7 (range
18–85) years for men, women, and all patients, respec-
tively. Plain radiographic changes were cortical thinning,
cortical bone loss, and patchy osteopenia. The conditions
associated with development of CRPS type I included eight
distal radius fractures (four were surgically treated), four
soft tissue tumor excisions, and four carpal tunnel syn-
drome surgery. Three patients had soft tissue hand trauma
due, respectively, to ﬁfth metacarpal fracture, crush injury
to the hand, and surgery for Dupuytren’s disease.
Patients were assessed by clinical examination and radi-
ographypriortotreatmentinitiationandattheposttreatment
follow-up, which was 2 weeks after the ﬁnal stellate gan-
glion blockade. They were divided into two groups accord-
ing to the latency from symptom onset and stellate ganglion
block initiation (28 weeks as the threshold). Group 1 (14
patients) and group 2 (eight patients) had a short and a long
mean duration between symptom onset and treatment,
respectively. The mean times from symptom onset to treat-
ment initiation were 17.0 ± 6.3 (range 6–28) weeks,
49.8 ± 17.6 (range 29–77) weeks, and 28.9 ± 19.7 (range
6–77) weeks for group 1, group 2, and all patients, respec-
tively. Patients were not allowed to take any medication.
Patients’ mean ages were 54.9 ± 20.6 (range 18–85) years
and 54.0 ± 16.2 (range 29–75) years for groups 1 and 2,
respectively.
Stellate ganglion blockade was performed three times
with an interval of 1 week between treatments. The pro-
cedure used the anterior paratracheal approach on the
cervical sympathetic chain without ﬂuoroscopic guidance
[9, 10]. A 22-gauge, 5-cm needle was inserted perpendic-
ular to the skin until bone contact was made and then
Table 1 Patient demographic values and etiologies
Age Gender Initial trauma Side Duration
(weeks)
47 F Hand trauma L 6
56 F Soft tissue tumor excision L 9
48 F Crush hand injury L 9
85 M Radius distal end fracture R 14
27 M Fifth metacarpal fracture L 15
70 F Soft tissue tumor excision R 16
38 M Radius distal end fracture
a L1 7
59 F Radius distal end fracture R 17
74 M Dupuytren’s contracture operation R 18
46 F Hand trauma R 20
43 M Carpal tunnel release L 21
85 M Radius distal end fracture R 22
18 F Carpal tunnel release L 26
73 M Radius distal end fracture
a R2 8
32 M Soft tissue tumor excision L 29
29 F Soft tissue tumor excision L 33
60 F Carpal tunnel release R 35
58 F Hand trauma R 48
75 M Radius distal end fracture
a R5 2
61 F Radius distal end fracture
a R5 2
67 F Radius distal end fracture R 72
50 F Carpal tunnel release L 77
M male, F female, R right, L left
a Surgically treated
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123withdrawn to rest anteriorly to the precervical fascia. A
volume of 15 ml of equal parts 0.5% bupivacaine (5 mg/
ml) and 1% prilocaine–hydrochloride (HCl) (20 mg/ml)
was used. After injection of a 0.5-ml test dose to exclude
intravascular positioning, the remainder of the appropriate
dose was administered. The patient was encouraged to lie
ﬂat for 3 min after the injection and then to sit up.
Pain intensity was evaluated before and 2 weeks after
the last of three stellate ganglion blockades using a 10-cm
visual analog scale (VAS) in which 0 represented no pain
and 10 represented the most severe pain. The range of
ﬂexion, extension, supination, and pronation of each
patient’s wrist joint was also recorded. Patients were asked
to perform simple range of motion (ROM) exercises during
the blockades. These consisted mainly of active and active-
assisted passive exercises on the wrist joint. After the fol-
low-up examination performed 2 weeks after the last stel-
late ganglion blockade, passive exercises along with a
rehabilitation program were started.
Statistical analysis
Statistical analysis was performed with Statistical Package
for Social Sciences 11.0 (SPSS 11.0, SPSS Inc., Chicago
IL, USA). The Wilcoxon signed-rank test was used to
compare wrist-joint ROM values before and 2 weeks after
the last blockade and to compare VAS values before and
2 weeks after the last blockade for all patients and for each
group. The Mann–Whitney U test was used for between-
group comparisons of mean VAS values. P\0.05 was
taken to indicate statistical signiﬁcance.
Results
Values pretreatment and 2 weeks postblockade ROM are
shown in Table 2. The blockade produced signiﬁcant
changes in ROM values for wrist ﬂexion, extension, supi-
nation, and pronation in all patients (P\0.001). Wrist
ﬂexion and extension improved from 50 ± 14 to
69 ± 8 and from 39 ± 13 to 59 ± 8, respectively.
Supination and pronation improved from 41 ± 12 to
63 ± 8 and from 50 ± 13 to 69 ± 8, respectively.
Pretreatment and 2 weeks postblockade VAS results for
both groups are presented in Table 3. Overall VAS
decreased from 8 ± 1t o1± 1 following stellate ganglion
blockade.
There was no signiﬁcant difference in baseline VAS
value between groups (P[0.05). Blockade signiﬁcantly
improved VAS values in all patients and in both treatment
groups (P\0.05); however, there was a signiﬁcant dif-
ference in postblockade VAS value between groups 1and 2
(P\0.05). No adverse effects to medications administered
or the procedure itself were documented during the pro-
cedure or follow-up.
Discussion
Invasive procedures, including nerve blocks, spinal cord
and peripheral nerve stimulation, chemical and surgical
sympathectomies, and deep brain stimulation have been
used to manage CRPS type I for some time [4]. Sympa-
thetic nervous system dysfunction is presumed to be an
Table 2 Wrist joint mean range of motion (ROM)
Group ROM
Wrist ﬂexion Wrist extension Supination Pronation
Before
blockade
After
blockade
P
value
Before
blockade
After
blockade
P
value
Before
blockade
After
blockade
P
value
Before
blockade
After
blockade
P
value
1 47.3 ± 13.7 68.8 ± 8.6 0.001 35.8 ± 11.6 59.4 ± 9.0 0.001 37.9 ± 10.8 62.9 ± 6.7 0.001 48.19 ± 12.4 68.1 ± 8.5 0.001
2 55.4 ± 13.4 70.5 ± 7.7 0.012 44.4 ± 13.9 57.5 ± 5.3 0.012 46.9 ± 11.4 63.6 ± 10.4 0.012 52.8 ± 14.6 71.1 ± 5.6 0.012
Overall 50.2 ± 13.8 69.4 ± 8.1 0.000 38.9 ± 12.8 58.7 ± 7.8 0.000 41.1 ± 11.6 63.1 ± 8.0 0.000 49.8 ± 13.0 69.2 ± 7.6 0.000
Table 3 Mean visual analog scores (VAS) pretreatment and postblockade
Group: duration to blockade initiation VAS score
Before blockade After blockade P value
1 Mean duration 17.0 ± 6.3 (range 6–28 weeks) 7.7 ± 1.1 (range 6–10) 0.9 ± 0.7 (range 0–2) 0.001
2 Mean duration 49.8 ± 17.6 (range 29–77 weeks) 7.9 ± 1.1 (range 7–10) 2.1 ± 1.3 (range 0–4) 0.012
Overall Mean duration 28.9 ± 19.7 (range 6–77 weeks) 7.8 ± 1.1 (range 6–10) 1.3 ± 1.1 (range 0–4) 0.000
Group 1: with a latency from symptom onset stellate ganglion blockade initiation shorter than mean latency. Group 2: with a latency from
symptom onset and stellate ganglion blockade initiation longer than mean latency
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123essential component of the syndrome [11], and sympathetic
blockade has been recommended as early as possible to
interrupt and reverse the process [12]. The primary goal of
this study was to evaluate the effects of stellate ganglion
blockade treatment on CRPS type I. Treatment produced a
statistically signiﬁcant difference in wrist ROM for all
patients (P\0.001). VAS values showed an overall
decrease from 8 ± 1t o1± 1 following treatment, and
there was a signiﬁcant difference in VAS value between
groups 1 and 2 (P\0.05), showing that there is a direct
relationship between symptom onset and treatment initia-
tion. Mean VAS reduction was 7 ± 1 (range 5–9), 6 ± 2
(range 3–9), and 7 ± 2 (range 3–9) in groups 1 and 2 and
overall, respectively.
This study was limited by a relatively small sample size
and a wide range of conditions causing CRPS type I.
However, as demonstrated in previous studies [13–15],
large sample sizes and even distribution of etiologies are
difﬁcult to achieve. Another weakness of the study was the
lack of long-term results of the blockades.
There is limited number of studies of stellate ganglion
blockade in the literature. Cepeda et al. [6, 14] published
two reviews. In 2002, they concluded that there are ques-
tions as to the efﬁcacy of local anesthetic sympathetic
blockade in treating CRPS because its efﬁcacy is based
mainly on case series [14]. Later in 2005, Cepeda et al. [6]
published a review that attempted to determine the likeli-
hood of pain alleviation after sympathetic blockade with
local anesthetics in the patient with CRPS, to assess how
long any beneﬁt persists, and to evaluate the incidence of
adverse effects. They searched the Cochrane Pain, Pallia-
tive and Supportive Care Register, the Cochrane Central
Register of Controlled Trials, Medline, EMBASE,
LILACS, conference abstracts of the World Congresses of
the International Association for the Study of Pain, and
bibliographies from retrieved articles for randomized con-
trolled trials that evaluated the effect of sympathetic
blockade with local anesthetics in children or adults to treat
RSD, causalgia, or CRPS. They found only two small
randomized double-blind studies that evaluated 23 patients
across both studies. The combined effect of the two trials
produced a relative risk (RR) to achieve at least 50% of
pain relief 30 min to 2 h after the sympathetic blockade of
1.17 [95% conﬁdence interval (CI) 0.80–1.72]. They stated
that it was not possible to determine the effect of sympa-
thetic blockade on long-term pain relief because the
authors of the two studies evaluated different outcomes.
They concluded that the study revealed a scarcity of pub-
lished evidence to support the use of local anesthetic
sympathetic blockade as the gold standard treatment for
CRPS. Also, the two randomized studies that met inclusion
criteria had very small sample sizes. Therefore, no con-
clusion concerning the effectiveness of this procedure
could be drawn, and there is a need to conduct randomized
controlled trials to address the value of sympathetic
blockade with local anesthetic for the treatment of CRPS.
Another review was published recently by Albazaz et al.
[18] in 2008. They stated that the review gives a synopsis
of CRPS and discusses the principles of management based
on the limited available literature on the subject. They
performed a literature search using electronic bibliographic
databases (Medline, EMBASE, PubMed Central) from
1970 to 2006 with the keywords: complex regional pain
syndrome, reﬂex sympathetic dystrophy, neuropathic pain,
and causalgia. Relevant articles from the reference lists in
retrieved articles were also studied. There were 3,771
articles. Of the 76 randomized controlled trials that were
identiﬁed, most were on the role of sympathetic blockade
in the treatment of CRPS (n = 13). In other studies, nine
were on bisphosphonates or calcitonin; four were on cog-
nitive behavioral therapy, physiotherapy, or occupational
therapy; three were on spinal cord stimulation; and two
each on acupuncture, vitamin C, and steroids. The
remaining studies were on miscellaneous therapy or com-
bination therapy, making it difﬁcult to draw any conclu-
sions on treatment effect. There was very little good
evidence in the literature to guide treatment of CRPS. The
authors concluded that early recognition and a multidisci-
plinary approach to management seems important in
obtaining a good outcome.
We found that the duration between the symptom onset
and therapy initiation played a major role in blockade
success. Similar to this study, in a prospective study of 25
patients who had carpal tunnel release, Ackerman and
Zhang [19] found that stellate ganglion blockade was sig-
niﬁcantly more effective in relieving pain associated with
CRPS type I when administered shortly after symptom
onset. They concluded that the treatment was less effective
when administered[16 weeks after symptom onset.
Seventy-one patients with reﬂex sympathetic dystrophy
of the lower extremities were studied over a 3-year period.
Of the 27 patients managed by conservative means, 11
(41%) showed signs of improvement, whereas of the 43
patients treated by sympathetic nerve blocks, 28 (65%)
experienced progress. The authors concluded that early
treatment with repeated sympathetic nerve blocks appears
to improve the long-term outcome [17]. Yokono et al. [20]
correlated the changes in three phase bone scintigraphy
(TPBS) with prognosis after sympathetic blockade in RSD
of the hand in 12 patients. They compared scintigraphy
obtained just before and after this series of sympathetic
blocks and evaluated the eventual recovery of hand func-
tion. In eight patients, blood ﬂow (phase 1) image of TPBS
decreased after the blockade. But others with normalized
blood ﬂow remained with mild hand contracture. These
results suggest that normalization of blood pool and
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123delayed image on scintigraphy is a predictor of subsequent
recovery after sympathetic blockade in RSD. Schu ¨rmann
et al. [16] evaluated the results of stellate ganglion block-
ade in 33 patients in CRPS type I. They report that mean
pain reduction was 2.3 points on the VAS. Seventeen
patients (51.5) experienced a reduction B50% of initial
pain, no signiﬁcant pain relief was observed in 13 patients
(39.4%), and three patients (9.1%) had no pain before the
blockade. These ﬁndings are contrary to our study, in
which we found a mean VAS reduction of 7 ± 2 (range 3–
9) overall. The reason for this maybe the injection tech-
nique or patient characteristics.
We report that stellate ganglion blockade successfully
relieved pain in patients with CRPS type I as indicated by a
signiﬁcant reduction in VAS values for all patients fol-
lowing the block (P\0.05). Price et al. [21] analyzed the
results of sympathetic ganglion block in seven patients.
They reported that local injection of an anesthetic produced
large reductions in pain intensity in six patients and con-
cluded that both magnitude and duration of pain reduction
should be closely monitored to provide optimal efﬁcacy in
procedures that use local anesthetics to treat CRPS. Bonelli
et al. [13], in a randomized trial of reﬂex sympathetic
dystrophy, found that the performance of intravenous
guanethidine block is of longer duration, and superior to
stellate ganglion block as regards some early pharmaco-
logical effects. However, their patients exhibited severe
reﬂex sympathetic dystrophy following peripheral nerve
lesions, and thus all belonged to CRPS type II.
Sympathetic block treatment may be particularly helpful
in cases in which, despite adequate doses of oral medica-
tion, pain limits a patient’s participation in physical and
occupational therapy [7]. Treatments aimed at pain
reduction and rehabilitation of limb function form the
mainstay of therapy [18]. In this study, stellate ganglion
blockade signiﬁcantly improved ROM values for wrist
ﬂexion, extension, supination, and pronation in all patients
(P\0.001). The treatment effectively cut the vicious
cycle of pain, immobilization, decreased joint motion, and
pain.
We concluded that treating CRPS type I with stellate
ganglion blockade successfully decreased VAS values and
increased wrist-joint ROM. We are of the opinion that our
study focuses on a district anatomical region and gives
evidence to guide treatment of CRPS type I, especially in
the hand and wrist. The duration between symptom onset
and therapy initiation was a major factor affecting the
success of the blockade. If other treatment modalities fail,
stellate ganglion blockade should be performed as early as
possible.
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